Atogepant's Impact on Migraine Days: New Study Insights
- MigraineMind
- Nov 23, 2025
- 1 min read
Research Summary
A recent study published in CPT Pharmacometrics & Systems Pharmacology explored how different doses of atogepant impact monthly migraine days (MMD) in patients with episodic or chronic migraine. Researchers developed a model using data from several clinical trials, which demonstrated that atogepant effectively reduces MMD by 90% by inhibiting the calcitonin gene-peptide receptor. The model, based on a modified normal distribution, described how MMD plateaued at Weeks 9-12, aligning with most Cmin exposures seen at a 10 mg daily dose. Interestingly, no significant efficacy difference was found between patients previously treated with oral migraine preventives and those who were treatment-naïve.
Study Details
👥 Research Team: Schlachter L et al.
📚 Published In: CPT Pharmacometrics Syst Pharmacol
📅 Publication Date: 2025 Nov 21
⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.